Cellectar Biosciences (FRA:NV40) Cyclically Adjusted FCF per Share: €-118.01 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:NV40 Cellectar Biosciences Inc FRA:NV40
23 GF Score
Price €0.25
! 1 Warning Sign
View Full Analysis

What is Cellectar Biosciences Cyclically Adjusted FCF per Share?

Cellectar Biosciences FRA:NV40 23 Cyclically Adjusted FCF per Share is €-118.01 as of Mar. 2026. GuruFocus rates FRA:NV40 with a GF Score™ of 23/100. The stock has 1 warning sign investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Cellectar Biosciences's adjusted free cash flow per share for the three months ended in Mar. 2026 was €-0.989. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €-118.01 for the trailing ten years ended in Mar. 2026.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 8.50% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 8.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Cellectar Biosciences was 22.90% per year. The lowest was 8.50% per year. And the median was 12.20% per year.

As of today (2026-08-03), Cellectar Biosciences's current stock price is €0.2515. Cellectar Biosciences's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was €-118.01. Cellectar Biosciences's Cyclically Adjusted Price-to-FCF of today is .


Cellectar Biosciences  (FRA:NV40) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Cellectar Biosciences Cyclically Adjusted FCF per Share Related Terms


Cellectar Biosciences Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Cellectar Biosciences's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cellectar Biosciences Cyclically Adjusted FCF per Share Chart

Cellectar Biosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1,520.38 -1,375.60 -1,139.61 -1,104.68 -102.26

Cellectar Biosciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1,056.94 -44.51 -55.41 -102.26 -118.01

FRA:NV40 vs DARE, NEUP, LGVN: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, Cellectar Biosciences's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cellectar Biosciences Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cellectar Biosciences's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Cellectar Biosciences's Cyclically Adjusted Price-to-FCF falls into.


FRA:NV40
23GF Score
Cellectar Biosciences Inc FRA:NV40
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cellectar Biosciences Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Cellectar Biosciences's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.989/330.2130*330.2130
=-0.989

Current CPI (Mar. 2026) = 330.2130.

Cellectar Biosciences Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 -1,693.000 241.018 -2,319.539
201609 -986.500 241.428 -1,349.285
201612 -742.333 241.432 -1,015.309
201703 -713.750 243.801 -966.729
201706 -649.250 244.955 -875.225
201709 -539.000 246.819 -721.115
201712 -398.000 246.524 -533.111
201803 -430.500 249.554 -569.643
201806 -363.167 251.989 -475.904
201809 -231.273 252.439 -302.526
201812 -150.750 251.233 -198.141
201903 -156.000 254.202 -202.647
201906 -102.435 256.143 -132.057
201909 -103.903 256.759 -133.628
201912 -78.000 256.974 -100.230
202003 -102.839 258.115 -131.565
202006 -59.543 257.797 -76.269
202009 -33.784 260.280 -42.861
202012 -32.263 260.474 -40.901
202103 -24.956 264.877 -31.112
202106 -32.426 271.696 -39.410
202109 -27.325 274.310 -32.894
202112 -19.569 278.802 -23.178
202203 -22.564 287.504 -25.916
202206 -27.029 296.311 -30.121
202209 -34.755 296.808 -38.667
202212 -21.539 296.797 -23.964
202303 -17.893 301.836 -19.575
202306 -18.533 305.109 -20.058
202309 -20.053 307.789 -21.514
202312 -17.530 306.746 -18.871
202403 -12.590 312.332 -13.311
202406 -10.542 314.175 -11.080
202409 -6.229 315.301 -6.524
202412 -7.496 315.605 -7.843
202503 -5.650 319.799 -5.834
202506 -2.757 322.561 -2.822
202509 -1.152 324.800 -1.171
202512 -0.875 324.054 -0.892
202603 -0.989 330.213 -0.989

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of €-118.01 mean?
Cellectar Biosciences (FRA:NV40) has a Cyclically Adjusted FCF per Share of €-118.01 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Cellectar Biosciences and its competitors.
Is Cellectar Biosciences' Cyclically Adjusted FCF per Share too high?
Cellectar Biosciences' current Cyclically Adjusted FCF per Share is €-118.01. Overall, Cellectar Biosciences has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Cellectar Biosciences' Cyclically Adjusted FCF per Share compare to DARE and NEUP?
Cellectar Biosciences' Cyclically Adjusted FCF per Share of €-118.01 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Cellectar Biosciences and its competitors. Cellectar Biosciences's current Cyclically Adjusted FCF per Share is €-118.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cellectar Biosciences stock overvalued right now?
Cellectar Biosciences (FRA:NV40) has a current Cyclically Adjusted FCF per Share of €-118.01. The current Cyclically Adjusted FCF per Share is €-118.01. Cellectar Biosciences' overall GF Score™ is 23/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Cellectar Biosciences (FRA:NV40), the current Cyclically Adjusted FCF per Share is €-118.01 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cellectar Biosciences Business Description

Other Exchanges CLRB:USA
Address 100 Campus Drive, Florham Park, NJ, USA, 07932
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. The products under development include Iopofosine, CLR 121125 ,CLR 121225 and others. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.
23GF Score

Get the complete analysis for FRA:NV40

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.25
Price